Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma

Neuro-Oncology

Volumn 17, Issue 5, 2015, Pages 697-707

  Green, Adam L ^a,b   Ramkissoon, Shakti H ^a,c   McCauley, Dilara ^d   Jones, Kristen ^a   Perry, Jennifer A ^a   Hsu, Jessie Hao Ru ^a   Ramkissoon, Lori A ^a   Maire, Cecile L ^a   Hubbell Engler, Benjamin ^a   Knoff, David S ^a   Shacham, Sharon ^d   Ligon, Keith L ^a,b,c   Kung, Andrew L ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Karyopharm Therapeutics   (United States)

^e Medical Center ^*  (United States)

Author keywords

apoptosis; exportin 1; glioblastoma; patient derived xenograft; SINE

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; EXPORTIN 1; KPT 251; KPT 276; SELINEXOR; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; CELL RECEPTOR; EXPORTIN 1 PROTEIN; HYDRAZINE DERIVATIVE; KARYOPHERIN; KPT-251; KPT-276; KPT-330; OXADIAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; DRUG EFFICACY; ENZYME ASSAY; FLOW CYTOMETRY; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NEUROTOXICITY; PHARMACODYNAMICS; TUMOR XENOGRAFT; TUNEL ASSAY; WESTERN BLOTTING; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINT; CELL DIFFERENTIATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; MACACA FASCICULARIS; MALE; METABOLISM; MOUSE; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; TUMOR CELL LINE;

ACRYLAMIDES; ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; HYDRAZINES; KARYOPHERINS; MACACA FASCICULARIS; MALE; MICE; OXADIAZOLES; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; TREATMENT OUTCOME; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928881005     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou303     Document Type: Article

References (30)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
4. Fangusaro J. Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J Child Neurol. 2009;24(11):1409-1417.
5. Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell. 2012;23(18):3673-3676.
6. Siddiqui N, Borden KL. mRNA export and cancer. Wiley Interdiscip Rev RNA. 2012;3(1):13-25.
7. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012;83(8): 1021-1032.
8. Huang WY, Yue L, Qiu WS, et al. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 2009;32(6):E315.
9. Noske A, Weichert W, Niesporek S, et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008; 112(8):1733-1743.
10. Yao Y, Dong Y, Lin F, et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep. 2009;21(1): 229-235.
11. Mutka SC, Yang WQ, Dong SD, et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 2009; 69(2):510-517.
12. Etchin J, Sun Q, Kentsis A, et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia. 2013;27(1):66-74.
13. Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120(9): 1765-1773.
14. Etchin J, Sanda T, Mansour MR, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Brit J Haematol. 2013; 161(1):117-127.
15. Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155-165.
16. Salas Fragomeni RA, Chung HW, Landesman Y, et al. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther. 2013;12(7): 1171-1179.
17. Inoue H, Kauffman M, Shacham S, et al. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol. 2013;189(6):2317-2326.
18. Shen A, Wang Y, Zhao Y, et al. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 2009;65(1):153-159; discussion 159-160.
19. Mehta S, Huillard E, Kesari S, et al. The central nervous system-restricted transcription factor olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell. 2011;19(3):359-371.
20. Wong J, Armour E, Kazanzides P, et al. High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities. Int J Radiat Oncol Biol Phys. 2008;71(5): 1591-1599.
21. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. Neuro Rx. 2005;2(4):541-553.
22. Walker CJ, Oaks JJ, Santhanam R, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013;122(17):3034-3044.
23. Rousselet A. Inhibiting Crm1 causes the formation of excess acentriolar spindle poles containing NuMA and B23, but does not affect centrosome numbers. Biol Cell. 2009;101(12): 679-693.
24. Sheng Z, Li L, Zhu LJ, et al. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med. 2010;16(6):671-677.
25. Maurer U, Charvet C, Wagman AS, et al. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 2006;21(6):749-760.
26. Sturm D, Bender S, Jones DT, et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer. 2014;14(2):92-107.
27. Gruber Filbin M, Dabral SK, Pazyra-Murphy MF, et al. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013; 19(11):1518-1523.
28. Sun Q, Carrasco YP, Hu Y, et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A. 2013;110(4):1303-1308.
29. Balducci M, Diletto B, Chiesa S, et al. Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study. Strahlenther Onkol. 2014;190(4):370-376.
30. Fontanilla HP, Pinnix CC, Ketonen LM, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 2012;35(1):51-57.